Lake Street calls DiaMedica Therapeutics (DMAC) a top idea in the analyst’s coverage universe for the 2026, citing a belief that DiaMedica is positioned to deliver “multiple meaningful catalysts” over the next 12-18 months. The firm keeps a Buy rating and $14 price target on DiaMedica shares.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DMAC:
- DiaMedica Therapeutics provides DM199 update following FDA meeting
- DiaMedica Advances DM199 Preeclampsia Program After FDA Pre-IND Meeting
- Buy Rating Affirmed for Diamedica Therapeutics Amid Promising DM199 Trial Progress
- Microsoft initiated, Home Depot downgraded: Wall Street’s top analyst calls
- DiaMedica Therapeutics initiated with an Overweight at Cantor Fitzgerald